Skip to main content

Hereditary Cancer in Clinical Practice

Ausgabe 1/2020

Inhalt (25 Artikel)

Open Access Research

Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53

Meis Omran, Lennart Blomqvist, Yvonne Brandberg, Niklas Pal, Per Kogner, Anne Kinhult Ståhlbom, Emma Tham, Svetlana Bajalica-Lagercrantz

Open Access Editorial

On the road with Henry Lynch

Steven A. Narod

Open Access Research

Group plus “mini” individual pre-test genetic counselling sessions for hereditary cancer shorten provider time and improve patient satisfaction

Jaclyn Hynes, Andrée MacMillan, Sara Fernandez, Karen Jacob, Shannon Carter, Sarah Predham, Holly Etchegary, Lesa Dawson

Open Access Research

Ubiquitous neurocognitive dysfunction in familial adenomatous polyposis: proof-of-concept of the role of APC protein in neurocognitive function

Marcia Roxana Cruz-Correa, Ana Cecilia Sala, Beatriz Cintrón, Jessica Hernández, Myrta Olivera, Adrian Cora, Constance M. Moore, Carlos A. Luciano, Marievelisse Soto-Salgado, Francis M. Giardiello, Stephen R. Hooper

Open Access Review

Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with BRCA1/2 pathogenic Germline gene variants: systematic review

Adriana M. Coletta, Susan K. Peterson, Leticia A. Gatus, Kate J. Krause, Susan M. Schembre, Susan C. Gilchrist, Banu Arun, Y. Nancy You, Miguel A. Rodriguez-Bigas, Larkin L. Strong, Karen H. Lu, Karen Basen-Engquist

Open Access Case report

An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube

Lučka Boltežar, Gorana Gašljević, Srdjan Novaković, Vida Stegel, Erik Škof

Open Access Case report

A rare missense variant in APC interrupts splicing and causes AFAP in two Danish families

Malene Djursby, Karin Wadt, Jane Hübertz Frederiksen, Majbritt Busk Madsen, Lukas Adrian Berchtold, Jane Preuss Hasselby, Gro Linno Willemoe, Thomas v. O. Hansen, Anne-Marie Gerdes

Open Access Research

Development and validation of next generation sequencing based 35-gene hereditary cancer panel

Wing Chan, Mianne Lee, Zhen Xuan Yeo, Dingge Ying, Keith A. Grimaldi, Craig Pickering, Michael M. S. Yang, Senthil K. Sundaram, Lawrence C. H. Tzang

Open Access Research

Expectations and psychological issues before genetic counseling: analysis of distress determinant factors

Zelmira Ballatore, Raffaella Bracci, Elena Maccaroni, Lucia Svarca, Francesca Bianchi, Laura Belvederesi, Cristiana Brugiati, Silvia Pagliaretta, Alberto Murrone, Federica Bini, Mirco Pistelli, Giulia Ricci, Rossana Berardi

Open Access Correction

Correction to: Expectations and psychological issues before genetic counseling: analysis of distress determinant factors

Zelmira Ballatore, Raffaella Bracci, Elena Maccaroni, Lucia Svarca, Francesca Bianchi, Laura Belvederesi, Cristiana Brugiati, Silvia Pagliaretta, Alberto Murrone, Federica Bini, Mirco Pistelli, Giulia Ricci, Rossana Berardi

Open Access Research

Increased risk for uterine cancer among first-degree relatives to Swedish gastric cancer patients

Johanna Samola Winnberg, Eva Rudd, Anne Keränen, Kristina Lagerstedt-Robinson, Annika Lindblom, Magnus Nilsson, Mats Lindblad, Krister Sjödahl

Open Access Research

Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study

Priyanka Bobbili, Temitope Olufade, Maral DerSarkissian, Rahul Shenolikar, Hong Yu, Mei Sheng Duh, Nadine Tung

Open Access Letter to the Editor

An American patient with polyposis carrying a Scandinavian AXIN2 pathogenic variant

Sarah K. Macklin-Mantia, Douglas L. Riegert-Johnson

Open Access Research

Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example

Kari Hemminki, Aayushi Srivastava, Sivaramakrishna Rachakonda, Obul Bandapalli, Eduardo Nagore, Akseli Hemminki, Rajiv Kumar

Open Access Research

Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population

Katarzyna Białkowska, Wojciech Marciniak, Magdalena Muszyńska, Piotr Baszuk, Satish Gupta, Katarzyna Jaworska-Bieniek, Grzegorz Sukiennicki, Katarzyna Durda, Tomasz Gromowski, Marcin Lener, Karolina Prajzendanc, Alicja Łukomska, Cezary Cybulski, Tomasz Huzarski, Jacek Gronwald, Tadeusz Dębniak, Jan Lubiński, Anna Jakubowska

Open Access Research

Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer

Sarah K. Macklin-Mantia, Stephanie L. Hines, Pashtoon M. Kasi

Open Access Research

Public support for healthcare-mediated disclosure of hereditary cancer risk information: Results from a population-based survey in Sweden

Andreas Andersson, Carolina Hawranek, Anna Öfverholm, Hans Ehrencrona, Kalle Grill, Senada Hajdarevic, Beatrice Melin, Emma Tham, Barbro Numan Hellquist, Anna Rosén

Open Access Research

Patients with unexplained mismatch repair deficiency are interested in updated genetic testing

Jessica Omark, Eduardo Vilar, Y Nancy You, Leslie Dunnington, Sarah Noblin, Blair Stevens, Maureen Mork

Open Access Research

Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation

Carol A. Mansfield, Kelly A. Metcalfe, Carrie Snyder, Geoffrey J. Lindeman, Joshua Posner, Sue Friedman, Henry T. Lynch, Steven A. Narod, D. Gareth Evans, Alexander Liede

Open Access Research

Biological and clinical impact of central nervous system hemangioblastomas in Chinese patients with von Hippel-Lindau disease: implications for treatment

Zhen Liu, Liang Li, Zhiqiang Yi, Hongzhou Duan, Runchun Lu, Chunwei Li, Lei Li, Kan Gong

Open Access Research

An in-depth exploration of the post-test informational needs of BRCA1 and BRCA2 pathogenic variant carriers in Asia

Jeanette Yuen, Si Ming Fung, Chin Leong Sia, Mallika Venkatramani, Tarryn Shaw, Eliza Courtney, Shao-Tzu Li, Jianbang Chiang, Veronique Kiak-Mien Tan, Benita Kiat-Tee Tan, Joanne Ngeow

Open Access Case report

Metachronous cutaneous squamous cell carcinoma in a young patient as the only presenting symptom to uncover Lynch syndrome with MLH1 Germline mutation

Karam Khaddour, Ryan C. Fields, Michael Ansstas, Ilana S. Rosman, George Ansstas

Open Access Research

Characteristics and genetic testing outcomes of patients with clinically suspected paraganglioma/pheochromocytoma (PGL/PCC) syndrome in Singapore

Kay Reen Ting, Pei Yi Ong, Samuel Ow Guan Wei, Rajeev Parameswaran, Chin Meng Khoo, Doddabele Srinivasa Deepak, Soo-Chin Lee

Open Access Research

Prevalence of RECQL germline variants in Pakistani early-onset and familial breast cancer patients

Muhammad Usman Rashid, Noor Muhammad, Faiz Ali Khan, Umara Shehzad, Humaira Naeemi, Naila Malkani, Ute Hamann

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.